The short version of MOD GRF(1-29) fits in a sentence. The long version — which is the one that helps — is below.
Reviewed 2026-08-01. Anything still debated is marked as such rather than presented as settled.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
Reconstitution is typically performed with sterile water or bacteriostatic water, added slowly against the vial wall. The resulting solution should be clear and colorless; cloudiness or visible particles suggest a problem with the material or the diluent. Once in solution, the peptide is less stable than the dry powder. Refrigerated storage at two to eight degrees Celsius is common for short-term holding, while freezing aliquots is described for longer periods.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white lyophilized powder | Visual descriptor; not a measure of purity |
| Solubility class | Freely soluble in water | Aqueous dissolution may require gentle mixing |
| Typical storage (powder) | −20 °C or below, desiccated | Protect from light and ambient moisture |
| Typical storage (solution) | 2–8 °C, short term | Freeze aliquots where longer holding is needed |
| Purity assessment | Reversed-phase HPLC, area percent | Values depend on column, gradient, and detection wavelength |
The compound emerged from work at a Canadian biotechnology firm in the early 2000s. Early human studies examined its effect on growth hormone and insulin-like growth factor 1 in healthy volunteers and in people with HIV-associated fat redistribution. Reports described sustained increases in both markers after a single injection. Development did not advance to regulatory approval, and the clinical programme was later discontinued. The molecule is now encountered mainly as a research chemical rather than a marketed medicine.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
At the pituitary, the peptide binds the growth hormone-releasing hormone receptor on somatotroph cells. Receptor activation raises intracellular cyclic AMP and triggers release of stored growth hormone. Somatostatin and other hypothalamic signals modulate this response. Negative feedback from insulin-like growth factor 1 also influences output. The same regulatory architecture operates with the native hormone. Whether the synthetic analog alters feedback dynamics over repeated exposure remains an open question. Most published receptor work uses cell models rather than intact human systems.
CJC-1295 is a synthetic peptide belonging to the growth hormone-releasing hormone analog family. It comprises twenty-nine amino acid residues derived from the N-terminal region of natural GHRH. The molecule incorporates several non-natural substitutions that increase resistance to enzymatic degradation. These modifications extend its activity compared with the native hormone fragment. Researchers use it to study pituitary growth hormone secretion in laboratory and clinical settings. This compound is distinct from native GHRH in its stability profile.
Two principal forms appear in the literature and in research supply. One carries a drug affinity complex, a maleimide-based group that forms a covalent bond with circulating albumin. This linkage slows clearance and produces a long-lasting elevation of peptide levels. The other form lacks that group and is often labeled MOD GRF(1-29). It has a much shorter circulation time. Both variants retain the same core receptor-binding sequence. Reported half-lives differ substantially between the two.
SQM commissioned a life-cycle analysis (LCA) which concluded that water consumption for SQM's lithium hydroxide and carbonate is significantly lower than the average consumption by production from the main ore-based process, using spodumene. A more general LCA suggests the opposite for extraction from reservoirs. The majority of brine based production is in the "lithium triangle" in South America.
Significant efforts have been focused on the mechanisms responsible for Aβ production, including the proteolytic enzymes gamma- and β-secretases which generate Aβ from its precursor protein, APP (amyloid precursor protein). Aβ circulates in plasma, cerebrospinal fluid (CSF) and brain interstitial fluid (ISF) mainly as soluble Aβ40. Amyloid plaques contain both Aβ40 and Aβ42, while vascular amyloid is predominantly the shorter Aβ40. Several sequences of Aβ were found in both lesions. Increases in either total Aβ levels or the relative concentration of both Aβ40 and Aβ42 (where the former is more concentrated in cerebrovascular plaques and the latter in neuritic plaques) have been implicated in the pathogenesis of both familial and sporadic Alzheimer's disease. Due to its more hydrophobic nature, the Aβ42 is the most amyloidogenic form of the peptide. However the central sequence KLVFFAE is known to form amyloid on its own, and probably forms the core of the fibril.
The IDF traces its roots to Jewish paramilitary organizations in the New Yishuv, starting with the Second Aliyah (1904 to 1914). The first such organization was Bar-Giora, founded in September 1907. Bar-Giora was transformed into Hashomer in April 1909, which operated until the British Mandate of Palestine came into being in 1920. Hashomer was an elitist organization with narrow scope, and was mainly created to protect against criminal gangs seeking to steal property. The Zion Mule Corps and the Jewish Legion, both part of the British Army of World War I, further bolstered the Yishuv with military experience and manpower, forming the basis for later paramilitary forces. After the 1920 Palestine riots against Jews in April 1920, the Yishuv leadership realised the need for a nationwide underground defense organization, and the Haganah was founded in June of the same year. The Haganah became a full-scale defense force after the 1936–1939 Arab revolt in Palestine with an organized structure, consisting of three main units—the Field Corps, Guard Corps, and the Palmach. During World War II, many Jews from the Yishuv enlisted in the British Armed Forces. Many of them served in the British Army, culminating in the formation of the Jewish Brigade. These would eventually form the backbone of the Israel Defense Forces, and provide it with its initial manpower and doctrine. Following Israel's Declaration of Independence, prime minister and defense minister David Ben-Gurion issued an order for the formation of the Israel Defense Forces on 26 May 1948.
Sources: en.wikipedia.org
==== Migration patterns ==== HIC can be useful in tracking animal migration. Animals with metabolically inert tissue (e.g. feathers or hair) synthesize that tissue using hydrogen from source water and food, but ideally do not incorporate subsequent water during migration. Because δD varies geographically, the difference between animal tissue δD and post-migration water δD, after accounting for the biological fractionation of assimilation, can provide information regarding animal movement. In monarch butterflies, for example, wing chitin is metabolically inert after it is built, so it can reflect the isotopic composition of the environmental water at the time and location of wing growth. This then creates a record of butterfly origin and can be used to determine migration distance. This approach can also be used in bats and birds, using hair and feathers, respectively. Since rainwater becomes depleted as elevation increases, this method can also track altitudinal migration. However, this is technically hard to do, and the resolution seems to be too poor to track small altitudinal changes. 2H is most useful in tracking movement of species between areas with large continental water variation, since species movement can be complicated by the similarity of local water δD between places. For example, source water from Baja California may have the same δD as water from Maine. Further, a proportion of the HIC in the tissue can exchange with water and complicate the interpretation of measurements.
Judge Marino Barbero indicted 39 people, eight of whom would be sentenced in 1997 by the Supreme Court to sentences ranging from eleven years in prison to six months in prison. A third corruption case that splashed the PSOE was the "Ibercorp case", known in February 1992 and also uncovered by the newspaper El Mundo, and the one involving governor of the Bank of Spain Mariano Rubio which forced the former Minister of Economy and Finance Carlos Solchaga, who had appointed him, to resign as deputy. The PSOE was so questioned that it "exhibited an almost total lack of credibility" when it filed the denunciation of a corruption case involving the Popular Party, the "Naseiro case", by the name of the "treasurer" of the PP Rosendo Naseiro.
== Epidemiology == Each year, more than 2.5 million people in the United States develop pressure ulcers. In acute care settings in the United States, the incidence of bedsores is 0.4% to 38%; within long-term care it is 2.2% to 23.9%, and in home care, it is 0% to 17%. Similarly, there is wide variation in prevalence: 10% to 18% in acute care, 2.3% to 28% in long-term care, and 0% to 29% in home care. There is a much higher rate of bedsores in intensive care units because of immunocompromised individuals, with 8% to 40% of those in the ICU developing bedsores. However, pressure ulcer prevalence is highly dependent on the methodology used to collect the data. Using the European Pressure Ulcer Advisory Panel (EPUAP) methodology there are similar figures for pressure ulcers in acutely sick people in the hospital. There are differences across countries, but using this methodology, pressure ulcer prevalence in Europe was consistently high, from 8.3% (Italy) to 22.9% (Sweden). A recent study in Jordan also showed a figure in this range. Some research shows differences in pressure-ulcer detection among white and black residents in nursing homes.
=== 2018–present === On January 9, 2018, construction workers broke ground on a new 5,100 square foot (470 m2) wound healing center at the hospital, it would be double the size of the old facility. The wound healing center was completed at the end of 2018 and included six treatment rooms, three hyperbaric chambers, waiting area and a lobby. On May 22, 2019, AdventHealth signed a definitive agreement to purchase Lake Wales Medical Center from Community Health Systems. On September 1, AdventHealth took over the management of Lake Wales Medical Center, it had purchased the hospital for $10,146,000 and renamed it AdventHealth Lake Wales. On January 1, 2021, all hospitals were required to have their chargemaster on its website by the Centers for Medicare & Medicaid Services. In early February, 2023, almost all of the AdventHealth hospitals had their chargemaster on their website, including AdventHealth Lake Wales.
Sources: en.wikipedia.org
Cool, dark, and dry conditions are standard, with storage at minus twenty degrees Celsius or below. Desiccant and sealed vials limit moisture uptake. Repeated warming and cooling of the container is generally avoided.
There is no single agreed limit, and laboratory practice varies widely. Refrigeration slows degradation, and freezing aliquots is often described for longer holding. Any visible cloudiness or precipitate indicates the solution should be discarded.
Mass spectrometry provides the most direct confirmation through molecular mass. Reversed-phase chromatography supports purity assessment, and peptide mapping or amino acid analysis can corroborate sequence. No single method establishes both purity and identity on its own.
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.